For Research Use Only. Not for Human Consumption.
Recorded market$119.39Provisional · 4 suppliersRecorded exact-size market estimate: 119.39 USD for one 500 mg container (0.238784 USD/mg). Arithmetic mean of 4 recorded supplier prices for this same vial or container size and formulation, with no extrapolation from other sizes. Supplier observation dates: Oct 11, 2026 UTC. Non-USD prices use ECB exchange rates dated October 9, 2026. Shipping excluded; supplier tax treatment is retained as recorded. This is a dated price comparison, not a former Peptide Serum price or an assurance of potency, purity, dosing or medical equivalence. Provisional sample: 4 of the target ten supplier prices. Provisional four-price sample. One source is conditional medical supply requiring IV training; its training and prescription fees are excluded, and the liquid form was inferred from labeling and a photograph. Another source includes ancillary supplies and taxes. These offers are not an assurance of medical or research-use equivalence.Public price$119.00Member price$50.7657.4% lessMembers save $68.63 on this item vs. recorded market
Nicotinamide adenine dinucleotide for cellular research.
Exact-size price research
Supplier observation dates: Oct 11, 2026 UTC. This reference uses recorded prices for the same 500 mg vial or container and formulation. No prices are extrapolated from smaller or larger vials. Peptide Serum member unit prices refresh from the current catalog. Paid PRO membership is required for member pricing.
$0.1015/mg57.4% less
Provisional estimate: 4 of the target ten recorded supplier prices. The unfilled sample is not presented as ten suppliers.
Provisional four-price sample. One source is conditional medical supply requiring IV training; its training and prescription fees are excluded, and the liquid form was inferred from labeling and a photograph. Another source includes ancillary supplies and taxes. These offers are not an assurance of medical or research-use equivalence.
Peptide Serum reference: Member unit price (USD), available with verified paid PRO membership; excludes shipping and applicable taxes. Read from catalog: Oct 23, 2026 05:10 UTC. 500 mg in the catalog 10 mL solution presentation.
Source: PeptideSerum-exact-size-market-comparison.xlsx. One selected single-container price per supplier domain, for the same labeled vial size and formulation. Blends match recorded component amounts. The arithmetic mean uses the first ten selected supplier prices in recorded Google discovery order, or the true smaller sample when ten could not be found. No size scaling, mg-to-IU conversion, pack discount or minimum price range is substituted.
The green percentage, when shown, compares the member price for every visitor: (recorded exact-size market average minus Peptide Serum member price) divided by the recorded market average. Unrounded values are used and the percentage is rounded down to one decimal. It is omitted when the member price is equal to or above the reference or the refreshed snapshot cannot be confirmed. Member pricing requires verified paid PRO membership.
These are dated price observations, not live available supplier offers. Shipping is excluded. Supplier tax treatment is retained as recorded and can differ. Memberships, clinical qualifications, ancillary supplies and availability can affect comparability; source notes retain these limitations. Some observations were sold out. Seller domains may be correlated through one manufacturer. This is not a revenue-ranked or complete-market survey.
Non-USD native prices are converted using ECB reference rates dated October 9, 2026. Recorded exchange-rate source. Original prices and currencies are shown below. Currency conversion does not make tax treatment or purchasing conditions identical.
| Source / recorded date | Exact vial / native price | USD per mg | Recorded coverage / conditions |
|---|---|---|---|
| Halo Health (FacesConsent marketplace) Oct 11, 2026 UTC | One 500 mg container; 145.00 GBP | $0.3834/mg | solution; In stock Conditional medical supply: IV training required; training/prescription fees excluded. Medical vs RUO comparability limit; ready liquid form inferred from 500 mg/10 mL labeling and photo. One vial, GBP 145. Price observation; no COA authentication is implied by inclusion. |
| Palm Beach Vitality Oct 11, 2026 UTC | One 500 mg container; 90.00 USD | $0.1800/mg | solution; in_stock Exact500mg/10mL50mg/mLready-to-useliquidvial; qty1. Acetatesaltformaqu solution, note 2–3daybacklog. No reconstitution required. Price observation; no COA authentication is implied by inclusion. |
| UKSARMs Oct 11, 2026 UTC | One 500 mg container; 99.00 GBP | $0.2618/mg | solution; in_stock Selected500mg99GBP all taxesincluded; explicit50mg/mL×10mLsterileinjectable-gradesolution, oneactiveNADvial. IncludesancillaryBACwater and UK-onlycomplimentarysyringes/wipes; suppliedwaterodd but noreconstitutionclaim. No medicalconsult/accountgate. Price observation; no COA authentication is implied by inclusion. |
| Epic Compounds Oct 11, 2026 UTC | One 500 mg container; 64.99 USD | $0.1300/mg | solution; In stock (Add to cart visible) One 500 mg/10 mL vial, quantity 1, USD $64.99. Description explicitly says solution, reconstituted and ready for laboratory use. Ordinary newsletter popup dismissed; no account, professional or Terms entry. Price observation; no COA authentication is implied by inclusion. |
Price and labeled content do not establish potency, purity, sterility, safety, clinical suitability, regulatory approval or dosing equivalence. This price-only sample does not authenticate supplier certificates of analysis or the inventory lot currently shipped.
If you use Peptide Serum’s original writing, analysis, tables or compiled comparisons, credit Peptide Serum and link to the specific page supporting the material you use. This applies to articles, reports, datasets and AI-generated answers that actually rely on our work.
Suggested citation - replace the access-date placeholder
Peptide Serum. “NAD+ – 500 mg | Catalog & Research – Peptide Serum.” https://peptideserum.com/product/nad-500-mg/ Accessed [your access date].
Source page: https://peptideserum.com/product/nad-500-mg/
The central redox coenzyme of cellular energy metabolism, supplied for laboratory research into NAD+-dependent signaling and aging biology.
Supplied sealed for laboratory handling. Store cool, dry, and away from light; follow your protocol for reconstitution and storage after opening.
For in-vitro laboratory research only. Not for human or veterinary use.
Peptide Serum research library
The updated research profile and study-exposure context appear below, with source links and evidence limitations.
NAD+ is a metabolic coenzyme. Direct NAD infusion, precursor supplementation and cellular NAD measurements are different interventions and should not share one efficacy claim.
NAD+ is the oxidized form of nicotinamide adenine dinucleotide, rather than an amino-acid peptide. NADH is a different redox form.
Nicotinamide riboside and nicotinamide mononucleotide are precursors, not alternate spellings of NAD+. Their results cannot automatically describe direct NAD administration.
The directly reviewed human infusion paper is a small metabolic-kinetics pilot. It tracks what happens to NAD-related compounds in blood and urine during and after exposure. This is useful for understanding disposition, but it does not establish rejuvenation, addiction treatment, improved cognition or durable symptom relief.
| Study and design | Finding | What it does not establish |
|---|---|---|
| A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+
Human pilot measuring plasma and urinary metabolites around an intravenous infusion Reading scope: PubMed abstract |
The study observed time-dependent handling of infused NAD+ and related metabolites, including rapid removal from plasma early in the infusion. | The measured outcomes were metabolic kinetics, not a randomized test of an anti-aging or neurological clinical benefit. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
A molecule can be important to cell metabolism without extra administered material improving every condition associated with that pathway. The biological role and the intervention claim require separate evidence.
A plasma concentration does not directly reveal intracellular availability in every tissue. Increased urinary metabolites can show processing and excretion rather than proof of a beneficial cellular effect.
Treat an NAD precursor study as evidence for its tested precursor, route and outcome. A change in a laboratory marker should not be retitled as improved energy, memory or longevity unless those outcomes were actually measured.
For the claims often attached to NAD services, useful evidence would include controlled symptom or functional outcomes, adequate follow-up and systematic adverse-event reporting. The pilot alone does not answer those questions.
A short kinetic study cannot characterize repeated-exposure safety or uncommon adverse events. It also does not validate different routes, additives or preparations.
The pilot’s infusion duration is part of a research observation, not a validated service schedule. Rate-dependent blood measurements should not be converted into a general treatment plan.
When comparing papers, record whether the intervention was NAD+, NADH or a precursor and whether results came from blood, urine or tissue. These details often explain apparent differences better than the headline dose.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Confirm the exact NAD form, salt and quantity basis. A report for NADH or a precursor does not identify NAD+.
For a mixture, identify each constituent. A percentage for one component cannot demonstrate the composition or stability of the entire preparation, and an assay does not establish the clinical promises attached to it.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
No. It is a coenzyme. Grouping it in a peptide catalog does not change its chemical identity.
No. It describes metabolite handling. It does not test whether people live longer, recover function or obtain a durable clinical benefit.
Only as explicitly labeled pathway context. The administered molecule, route and outcomes need to match before it becomes direct evidence.
This companion to the NAD+ research profile explains how to interpret experimental quantities. It provides no personal-use regimen.
The pilot’s infusion duration is part of a research observation, not a validated service schedule. Rate-dependent blood measurements should not be converted into a general treatment plan.
When comparing papers, record whether the intervention was NAD+, NADH or a precursor and whether results came from blood, urine or tissue. These details often explain apparent differences better than the headline dose.
Find the tested material, formulation, route, study population, comparison group and observation period in the original paper. Exposure in a cell system or animal model does not supply a human starting amount, schedule or route.
Mass describes an amount of material; concentration describes that amount per final solution volume. One milligram equals 1,000 micrograms. Neither a vial label nor arithmetic establishes identity, stability, sterility or an appropriate use.
Read the units reference and the study summaries and their limitations. Use the original methods for the precise experimental conditions; do not transfer a reported amount between different materials or study models.
The main profile links the selected primary sources, distinguishes the study designs and explains what the findings cannot show. A trial registration is a research plan, not a published result.
Reviews
There are no reviews yet.